#neoadjuvant — Sunday, March 01, 2026 (1 items)
| 0 | 💬 0 |
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.
(nature.com)
|
Nature Medicine 2026-03-01 | #immunotherapy #melanoma #biomarker #neoadjuvant #checkpoint inhibitor |